Karen Savage, Vice President and Milford site head, said, “The manufacture of biotherapeutics is rapidly evolving and requires novel technical solutions to match the increasing complexity. The Company’s new site in Milford, MA is greatly amplifying our ability to develop new technologies and offer clients highly innovative solutions combined with our renowned and long-standing expertise.”
Rentschler Biopharma is qualifying the Milford site as a multi-product manufacturing facility, enabling the company to diversify capabilities and to effectively address client requirements.
Dr. Jesús Zurdo, senior vice president Innovation and Venture Partnerships, said, “At Rentschler Biopharma, we are working to improve our processes and implement new technologies with the goal of enabling better, faster, more cost-effective development and production for our clients. The integration of the methodologies being presented at BPI with faster cell line development workflows and streamlined fit-for-purpose process development could dramatically transform overall biotherapeutic development timelines and increase bioprocessing efficiency.”